✦ LIBER ✦

Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

✍ Scribed by Birgitta Olsson, Johan Szamosi

Book ID: 119926333
Publisher: Springer International Publishing AG
Year: 2001
Tongue: English
Weight: 165 KB
Volume: 40
Category: Article
ISSN: 0312-5963
DOI: 10.2165/00003088-200140020-00005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-Daily, Extended-Release Formulation

Once-Daily, Extended-Release Formulations of Antimuscarinic Agents in the Treatment of Overactive Bladder: A Review

✍ Eric S. Rovner; Alan J. Wein 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 212 KB

A new once-daily formulation of tolterod

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder

✍ S. Swift; A. Garely; T. Dimpfl; C. Payne; on behalf of the Tolterodine Study Gro 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 91 KB

PUK20 A COST EFFECTIVENESS ANALYSIS OF S

PUK20 A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

✍ HH Kang; JY Bae; SY Park; HS Sohn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Steady-State Pharmacokinetic Comparison

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine Formulation in Patients with Chronic Moderate-to-Severe Pain

✍ Russell K. Portenoy; Andréa Sciberras; Lise Eliot; Gordon Loewen; Jackie Butler; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Pharmacokinetics of a New Once-Daily Con

Pharmacokinetics of a New Once-Daily Controlled-Release Formulation of Aceclofenac in Korean Healthy Subjects Compared with Immediate-Release Aceclofenac and the Effect of Food

✍ Soo Kyung Bae, Soo-Hwan Kim, Hae Won Lee, Sook Jin Seong, Su-Yeon Shin, Sang Hun 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 149 KB

PKU2: IMPROVEMENTS IN CLINICAL OUTCOMES,

PKU2: IMPROVEMENTS IN CLINICAL OUTCOMES, HEALTH-RELATED QUALITY OF LIFE (HRQoL) AND SYMPTOM BOTHER FOR OVERACTIVE BLADDER PATIENTS TREATED WITH A NEW ONCE-DAILY FORMULATION OF OXYBUTYNIN

✍ D Lubeck; L Prebil; L Potter; P Peeples 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB